DistantNews
Support us
Kolon Tissuegene Shares Rebound Over 7% After Clinical Trial Setback
🇰🇷 South Korea /Health & Science

Kolon Tissuegene Shares Rebound Over 7% After Clinical Trial Setback

From Chosun Ilbo · () Korean

Translated from Korean, summarized and contextualized by DistantNews.

At a glance

News Sources not specified Context piece
  • Kolon Tissuegene shares rose over 7% after a seven-day decline, rebounding from a previous drop.
  • The stock's recovery is attributed to the market perceiving that the negative impact of its U.S. Phase 3 clinical trial results for 'TG-C' has already been factored in.
  • The company's osteoarthritis cell gene therapy, 'TG-C,' faced a significant price drop following the announcement of its clinical trial results.

Kolon Tissuegene shares have shown a strong rebound, rising more than 7% after a seven-day slump. The company's stock experienced a sharp decline following the announcement of the top-line results from the U.S. Phase 3 clinical trial for its osteoarthritis cell and gene therapy, 'TG-C.'

However, the market sentiment appears to have shifted, with investors now believing that the negative news has been fully priced into the stock. This perception has fueled buying interest at lower prices, leading to the current recovery.

As of late morning on the 27th, Kolon Tissuegene was trading at 16,180 won on the KOSDAQ, marking an increase of 1,180 won, or 7.87%, from the previous trading day. This upward movement suggests a renewed confidence in the company's prospects despite the earlier clinical trial setback.

DistantNews Editorial

Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog